Orphan designation: nicotinamide mononucleotide Treatment of sickle cell disease, 20/06/2023 Positive
EU/3/23/2786 - orphan designation for treatment of sickle cell disease
- EU/3/23/2786 - orphan designation for treatment of sickle cell disease
nicotinamide mononucleotide
OrphanHuman
Lgd
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases. - The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:
EMA list of opinions on orphan medicinal product designation
EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform: